Douglas A. Milroy
Known title: DirectorCIK: 0001381551
Associated companies
Transaction History
| DCI | ▲ Buy | Grant | 900 | $0 | 1/2/2026 | View on chart |
| DCI | ▲ Buy | Grant | 1,300 | $0 | 1/2/2025 | View on chart |
| DCI | ▲ Buy | Grant | 1,200 | $0 | 1/2/2024 | View on chart |
| DCI | ▲ Buy | Option Exercise | 13,200 | $558K | 8/30/2023 | View on chart |
| DCI | ▼ Sell | Open Market | 26,300 | $1.7M | 8/30/2023 | View on chart |
| DCI | ▲ Buy | Option Exercise | 13,100 | $419K | 8/30/2023 | View on chart |
| DCI | ▲ Buy | Grant | 1,300 | $0 | 1/3/2023 | View on chart |
| DCI | ▲ Buy | Grant | 1,200 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Morgan Stanley Raises DCI Target to $95 After Earnings Beat
Donaldson reported an earnings beat and announced a new share buyback plan, which has drawn positive attention from analysts. Morgan Stanley maintained its Equal-Weight rating but raised its price target to $95, reflecting confidence in the company's durable cash flow. The stock is currently trading near its 52-week low, a level where some analysts suggest it may be undervalued.
Morgan Stanley Raises DCI Target to $95 After Earnings Beat. Donaldson reported an earnings beat and announced a new share buyback plan, which has drawn positive attention from analysts. Morgan Stanley maintained its Equal-Weight rating but raised its price target to $95, reflecting confidence in the company's durable cash flow. The stock is currently trading near its 52-week low, a level where some analysts suggest it may be undervalued.